 TEL AVIV, Israel, Dec. 29, 2020 GLOBE NEWSWIRE -- VBL Therapeutics Nasdaq: VBLT today announced the expansion of its ongoing OVAL Phase 3 study investigating ofranergene obadenovec VB-111, for the treatment of platinum-resistant ovarian cancer into Europe, where the first patient has now been enrolled. The study continues to actively recruit patients in the U.S. and Israel, with over 200 patients enrolled to date. 